- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
CTC Counts Demonstrate Selection Value in Metastatic Breast Cancer
December 6th 2018, 11:40pm
San Antonio Breast Cancer Symposium
The use of circulating tumor-cell counts demonstrated strong value for selecting endocrine therapy versus chemotherapy for patients with estrogen receptor–positive, HER2-negative metastatic breast cancer.
Dr. Bidard on the Clinical Utility of Circulating Tumor Cell Count in Breast Cancer
December 6th 2018, 7:39pm
San Antonio Breast Cancer Symposium
Francois-Clement Bidard, MD, PhD, professor, medical oncologist, Institut Curie, discusses the clinical utility of circulating tumor cell count (CTC) in breast cancer at the 2018 San Antonio Breast Cancer Symposium.
Dr. Vicini on Partial Breast Irradiation Versus Whole Breast Irradiation in Women With Early-Stage Breast Cancer
December 6th 2018, 7:36pm
San Antonio Breast Cancer Symposium
Frank A. Vicini, MD, radiation oncologist, 21st Century Oncology of Michigan, compares the use of partial breast irradiation (PBI) with that of whole breast irradiation (WBI) in women with early-stage breast cancer at the 2018 San Antonio Breast Cancer Symposium.
PD-L1 Immune Cell Expression Critical to Atezolizumab Efficacy in TNBC
December 6th 2018, 6:53pm
San Antonio Breast Cancer Symposium
Improvements observed in progression-free survival and overall survival with the addition of first-line atezolizumab to nab-paclitaxel in patients with metastatic triple negative breast cancer or inoperable locally advanced TNBC are exclusive to those patients with PD-L1 expression ≥1% in immune cells.
Earlier Adjuvant Chemotherapy Benefits Patients With TNBC
December 6th 2018, 3:32am
San Antonio Breast Cancer Symposium
Delayed treatment with chemotherapy of more than 30 days after surgery for patients with triple-negative breast cancer is associated with worse survival rates and outcomes than those who receive adjuvant chemotherapy within 30 days of their procedure.
Dr. Litton on a Study of Neoadjuvant Talazoparib for Patients With BRCA-Mutated TNBC
December 6th 2018, 1:51am
San Antonio Breast Cancer Symposium
Jennifer Litton, MD, associate professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses a neoadjuvant study of talazoparib (Talzenna) for patients with BRCA1/2 mutated triple-negative breast cancer (TNBC) during the 2018 San Antonio Breast Cancer Symposium.
Dr. Hershman on Adherence to Cardiovascular Medication and Cardiovascular Events in Breast Cancer
December 6th 2018, 1:50am
San Antonio Breast Cancer Symposium
Dawn Hershman, MD, MS, professor of Medicine and Epidemiology, Columbia University Medical Center, leader of the breast cancer program at NewYork-Presbyterian/Columbia University Irving Medical Center, discusses the association between cardiovascular medication and cardiovascular events following a diagnosis of early-stage breast cancer during the 2018 San Antonio Breast Cancer Symposium.
Association Between pCR and Neoadjuvant Chemo Shows Improved Breast Cancer Outcomes
December 6th 2018, 12:51am
San Antonio Breast Cancer Symposium
Pathologic complete response following neoadjuvant chemotherapy appeared to be associated with improved survival outcomes among patients with breast cancer.
No Survival Benefit With Adjuvant Capecitabine in Early-Stage TNBC
December 6th 2018, 12:45am
San Antonio Breast Cancer Symposium
Adjuvant treatment with capecitabine in patients with early-stage triple-negative breast cancer did not significantly improve disease-free or overall survival compared with observation, according to results from the phase III GEICAM/CIBOMA trial that were presented at the 2018 San Antonio Breast Cancer Symposium.
T-DM1 Likely New Adjuvant Standard in High-Risk HER2+ Breast Cancer
December 6th 2018, 12:01am
San Antonio Breast Cancer Symposium
Ado-trastuzumab emtansine reduced the risk of invasive disease recurrence or death by 50% compared with trastuzumab as an adjuvant treatment for patients with HER2-positive early breast cancer who had residual invasive disease following neoadjuvant therapy.
Venetoclax/Rituximab Combo Achieves Durable, High MRD-Negative Status in CLL
December 5th 2018, 3:26am
ASH Annual Meeting and Exposition
The combination of venetoclax and rituximab for relapsed/refractor chronic lymphoblastic leukemia produced high rates of undetectable minimal residual disease, which was associated with prolonged progression-free survival, a new analysis of a randomized trial showed.
Competition Grows in Anti-BCMA CAR Pipeline for Multiple Myeloma
December 5th 2018, 3:10am
ASH Annual Meeting and Exposition
A multitude of BCMA-targeted CAR T-cell therapies are currently in development, each demonstrating different efficacy and safety profiles and each with different constructs.
Mutation in BCL2 Protein Confers Resistance to Venetoclax
December 4th 2018, 8:34pm
ASH Annual Meeting and Exposition
A newly discovered recurrent mutation in the B-cell leukemia/lymphoma 2 protein mediates clinical resistance to venetoclax in patients with chronic lymphocytic leukemia.
Daratumumab Plus Rd New Frontline Standard in Transplant-Ineligible Myeloma
December 4th 2018, 8:33pm
ASH Annual Meeting and Exposition
The triplet of daratumumab, lenalidomide, and dexamethasone reduced the risk of disease progression or death by 44% compared with lenalidomide plus dexamethasone in newly diagnosed patients with multiple myeloma who were not candidates for high-dose chemotherapy and autologous stem-cell transplant.
Rivaroxaban May Reduce Blood Clot Risk During Active Systemic Cancer Therapy
December 4th 2018, 8:33pm
ASH Annual Meeting and Exposition
Rivaroxaban may significantly reduce venous thromboembolism occurrence among patients actively being treated with systemic therapy, according to results from the phase IIIb CASSINI trial.
High MRD-Negative Rates Seen with Venetoclax in Patients With Relapsed/Refractory CLL
December 4th 2018, 8:33pm
ASH Annual Meeting and Exposition
Patients with relapsed/refractory chronic lymphoblastic leukemia treated with single-agent venetoclax attained high rates of minimal residual disease in peripheral blood and bone marrow.
Ibrutinib/Rituximab Improves OS, PFS Versus FCR for Untreated CLL
December 4th 2018, 8:32pm
ASH Annual Meeting and Exposition
The combination of ibrutinib and rituximab significantly improved overall survival and progression-free survival compared with standard fludarabine, cyclophosphamide, and rituximab for younger patients with chronic lymphocytic leukemia.
Selinexor Induces Responses in a Quarter of Patients with Heavily Pretreated MM
December 4th 2018, 8:17am
ASH Annual Meeting and Exposition
A Selinexor combination regimen induced an overall response rate of 26.2% in heavily pretreated patients with penta-refractory multiple myeloma.
Dr. Poeschel on 6 Versus 4 Cycles of R-CHOP in Frontline DLBCL
December 4th 2018, 7:42am
ASH Annual Meeting and Exposition
Viola Poeschel, MD, department of hematology, oncology and rheumatology, Saarland University Medical School, Germany, discusses outcomes of patients with diffuse large B-cell lymphoma (DLBCL) who were treated with 4 cycles of R-CHOP during the 2018 ASH Annual Meeting.
Dr. Shah on Initial Results for bb21217 in Multiple Myeloma
December 4th 2018, 7:39am
ASH Annual Meeting and Exposition
Nina Shah, MD, associate professor of medicine at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses initial results from a phase I clinical trial of bb21217, a next-generation anti-BCMA CAR T-cell therapy, in patients with multiple myeloma during the 2018 ASH Annual Meeting.